Literature DB >> 8356539

[Review of a technic for the estimation of area under the concentration curve in pharmacokinetic analysis].

P Bourget1, J M Delouis.   

Abstract

The determination of the area under concentration-time curve (AUC) is the most important parameter of a non-compartmental pharmacokinetic analysis. The calculation of AUC is usually performed by the trapezoidal rule. The aim of this work is to examine the reliability of this method still considered as a reference. The trapezoidal rule was compared to a selection of calculation methods often owning to other fields of research i.e., rectangular rule, Simpson and Tchebychev rules and log trapezoidal rule. The specific interest and limits of each method were discussed according to the kind and the type of pharmacokinetic profiles i.e., logarithmic or nonlogarithmic and the number of concentration-time couples. We obtained the following results: 1) The rectangular rule is the most simple and less effective method. 2) The trapezoidal rule remains an interesting method particularly when the profile is monologarithmic or nonlogarithmic. The efficacy of this method increases with the number of points of the pharmacokinetic profile. 3) The Simpson and the Tchebychev rules give very good results particularly when the number of points is higher than 7 and 6 respectively. 4) The log trapezoidal rule is an excellent method for the treatment of a logarithmic profile. 5) Both Tchebychev and log trapezoidal rules give accurate results when compared to the true AUC values. Further, it must be pointed out that this determination is depending on an arbitrary choice of points. Finally, the trapezoidal rule is not always the best method to determine AUC. If the analyst has only a pocket-calculator, he will obtain best results with the Simpson method than with the trapezoidal rule.(ABSTRACT TRUNCATED AT 250 WORDS)

Mesh:

Substances:

Year:  1993        PMID: 8356539

Source DB:  PubMed          Journal:  Therapie        ISSN: 0040-5957            Impact factor:   2.070


  7 in total

1.  Pharmacokinetic study of conventional sorafenib chemoembolization in a rabbit VX2 liver tumor model.

Authors:  Ahmad Parvinian; Leigh C Casadaban; Zane Z Hauck; Richard B van Breemen; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2015 May-Jun       Impact factor: 2.630

2.  Structural and pharmacological evaluation of a novel non-nucleoside reverse transcriptase inhibitor as a promising long acting nanoformulation for treating HIV.

Authors:  Shalley N Kudalkar; Irfan Ullah; Nicole Bertoletti; Hanna K Mandl; José A Cisneros; Jagadish Beloor; Albert H Chan; Elias Quijano; W Mark Saltzman; William L Jorgensen; Priti Kumar; Karen S Anderson
Journal:  Antiviral Res       Date:  2019-04-26       Impact factor: 5.970

3.  Disposition of a new rate-controlled formulation of prazosin in the treatment of hypertension during pregnancy: transplacental passage of prazosin.

Authors:  P Bourget; H Fernandez; D Edouard; A Lesne-Hulin; F Ribou; C Baton-Saint-Mleux; C Lelaidier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1995 Jul-Sep       Impact factor: 2.441

4.  Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection.

Authors:  Shalley N Kudalkar; Jagadish Beloor; Albert H Chan; Won-Gil Lee; William L Jorgensen; Priti Kumar; Karen S Anderson
Journal:  Mol Pharmacol       Date:  2017-02-06       Impact factor: 4.436

5.  Conventional versus drug-eluting embolic transarterial chemoembolization with doxorubicin: comparative drug delivery, pharmacokinetics, and treatment response in a rabbit VX2 tumor model.

Authors:  Ron C Gaba; Ramzy C Khabbaz; Ruth N Muchiri; Joseph D Morrison; Lobna Elkhadragy; William M Totura; Jonathan P Samuelson; Herbert E Whiteley; Ryan L Deaton; Peter L Nguyen; Maria Sverdlov; Jeremy J Johnson; Richard B van Breemen; R Peter Lokken
Journal:  Drug Deliv Transl Res       Date:  2021-04-16       Impact factor: 4.617

6.  Long-acting and extended-release implant and nanoformulations with a synergistic antiretroviral two-drug combination controls HIV-1 infection in a humanized mouse model.

Authors:  Jagadish Beloor; Shalley N Kudalkar; Gina Buzzelli; Fan Yang; Hanna K Mandl; Jyothi K Rajashekar; Krasimir A Spasov; William L Jorgensen; W Mark Saltzman; Karen S Anderson; Priti Kumar
Journal:  Bioeng Transl Med       Date:  2021-06-26

7.  New Preservative-Free Formulation for the Enhanced Ocular Bioavailability of Prostaglandin Analogues in Glaucoma.

Authors:  Gabriel Alviset; Yohann Corvis; Karim Hammad; Josiane Lemut; Marc Maury; Nathalie Mignet; Vincent Boudy
Journal:  Pharmaceutics       Date:  2022-02-20       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.